نتائج البحث - "Robert Z. Orlowski"

1

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

المصدر: Kumar, S K, Facon, T, Usmani, S Z, Plesner, T, Orlowski, R Z, Touzeau, C, Basu, S, Bahlis, N J, Goldschmidt, H, O'Dwyer, M E, Venner, C P, Weisel, K, Hulin, C, Karlin, L, Preis, M, Broyl, A, Renwick, W, Hansson, M, Krevvata, M, Wang, J, Van Rampelbergh, R, Ukropec, J, Uhlar, C M, Kobos, R & Perrot, A 2020, ' Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) : The Phase 3 Maia Study ', Blood, vol. 136, no. Suppl. 1, pp. 24-26 . https://doi.org/10.1182/blood-2020-134847Test

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Immunology, Daratumumab, Cell Biology, Hematology, Newly diagnosed, medicine.disease, Biochemistry, Transplant ineligible, Internal medicine, medicine, In patient, business, Multiple myeloma, Dexamethasone, Lenalidomide, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5896bbe9c1a891d488ec422553d253f1Test
https://doi.org/10.1182/blood-2020-134847Test

2

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

المصدر: Perrot, A, Facon, T, Kumar, S, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N J, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M E, Venner, C P, Weisel, K, Mace, J R, Raje, N S, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Liu, K, Fastenau, J, Gries, K S, Ho, K F, Mistry, P, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S Z 2021, ' Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone : Update of the Phase 3 MAIA Trial ', Blood, vol. 138, no. Suppl. 1, 1655 . https://doi.org/10.1182/blood-2021-144421Test

مصطلحات موضوعية: Health related quality of life, Oncology, medicine.medical_specialty, business.industry, Immunology, Daratumumab, Cell Biology, Hematology, Newly diagnosed, medicine.disease, Biochemistry, Transplant ineligible, Internal medicine, Medicine, business, Multiple myeloma, Dexamethasone, Lenalidomide, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b967409a0946fad3fc6d9ba7892b94Test
https://doi.org/10.1182/blood-2021-144421Test

3

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

المصدر: Blood. 136:45-46

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Bortezomib, Immunology, Daratumumab, Cell Biology, Hematology, Dara, medicine.disease, Biochemistry, Maintenance therapy, Internal medicine, medicine, In patient, business, Dexamethasone, Multiple myeloma, medicine.drug, Lenalidomide

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9fe9e2d6e52bd67066c03ba26e4971b8Test
https://doi.org/10.1182/blood-2020-137109Test

4

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

المصدر: Blood. 134:691-691

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Leukopenia, business.industry, Bortezomib, Immunology, Daratumumab, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, Transplantation, Internal medicine, medicine, medicine.symptom, business, Dexamethasone, Multiple myeloma, Lenalidomide, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2a6beafe1bafc9271bbf0949d95869efTest
https://doi.org/10.1182/blood-2019-123465Test

5

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

المصدر: Bahlis, N J, Facon, T, Usmani, S Z, Kumar, S K, Plesner, T, Orlowski, R Z, Touzeau, C, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M E, Venner, C P, Weisel, K, Krevvata, M, Pei, H, Wang, J, Van Rampelbergh, R, Ukropec, J, Uhlar, C M, Kobos, R & Perrot, A 2019, ' Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant : Updated Analysis of Maia ', Blood, vol. 134, no. Suppl. 1, 1875 . https://doi.org/10.1182/blood-2019-123426Test

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Leukopenia, business.industry, Immunology, Daratumumab, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, Chemotherapy regimen, Transplantation, Internal medicine, medicine, medicine.symptom, business, Dexamethasone, Multiple myeloma, medicine.drug, Lenalidomide